Key Highlights

  • PacBio (NASDAQ:PACB) rallied 82.19% over one month in published market data as of October 28, 2026, including 48.35% in the latest week and 18.98% in the latest session.
  • Partner announcements drove the month: EpiSign's METRIC 5-base launch on September 30, an EpiSign and Geneyx partnership on October 5, and Verily and TychoBio collaborations on October 20.
  • TychoBio will use HiFi and Kinnex long-read RNA sequencing on more than 10,000 samples, and the Verily collaboration is multi-year with no financial terms disclosed.
  • Second quarter 2026 revenue was USD 39.0 million with cash and investments of USD 236.9 million, and full-year revenue guidance is USD 155 million to USD 165 million.

What Moved the Stock

The rally at PacBio (NASDAQ:PACB) came from partner news built on its HiFi long-read sequencing, not from a company earnings release. EpiSign launched METRIC 5-base software for DNA methylation analysis on PacBio HiFi data on September 30, 2026, and on October 5 EpiSign and Geneyx Genomex announced a partnership extending episignature analysis for over 300 disorders. On October 20 PacBio announced a multi-year collaboration with Verily Health to build AI-ready clinico-genomic datasets, and TychoBio will sequence over 10,000 samples for RNA therapy design. No company announcement explains the 18.98% gain on October 28. EpiSign's software also supports Illumina and Oxford Nanopore data, so the partner news is not exclusive. A Sampled contract with the U.S. Department of Veterans Affairs worth up to USD 27.1 million over five years had also moved the shares two days earlier, as reported.

Quarterly Numbers

In the second quarter of 2026, reported on August 5, revenue was USD 39.0 million versus USD 39.8 million a year earlier, with consumables up to USD 20.1 million and instruments down to USD 12.8 million. The GAAP net loss was USD 44.7 million, GAAP gross margin fell to 32% from 37%, and Vega placements dropped to 26 from 38 while Revio placements rose to 20. The company cited higher compute and memory costs and Vega manufacturing transition costs. The SPRQ-Nx chemistry rollout lists whole genome sequencing at USD 345 per genome. PacBio has cut costs through a restructuring that streamlines marketing and research and development, and annualized Revio pull-through was about USD 202,000 per system. Whole genome sequencing on the SPRQ-Nx chemistry is listed at USD 345 per genome, a price investors will compare with rivals.

Risks and Next Steps

Collaboration headlines carry no disclosed revenue, so the link to sales is indirect. Margins are falling, the net loss is large, and cash fell from USD 314.7 million a year earlier to USD 236.9 million. After an 82.19% month and 106.74% over three months, a miss on November 4, 2026, when third quarter results are due, could reverse gains. PacBio (NASDAQ:PACB) also faces competition in sequencing and exposure to research funding. The company set a webcast for the third quarter call without issuing preliminary results. Pricing pressure from rivals and customer dependence on research budgets are further risks, and a weak report would meet a stock that has already doubled.

Where Things Stand

PacBio (NASDAQ:PACB) rallied 82.19% because a run of partner and collaboration announcements revived interest in long-read sequencing for AI and rare disease, not because of improved financials. The October 28 jump of 18.98% had no stated cause. The balance of evidence is mixed: cash of USD 236.9 million gives time, but revenue is flat and margins are falling. The next test is the third quarter report on November 4, 2026.